aminoglutethimide has been researched along with Menopause in 113 studies
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer." | 10.16 | Tamoxifen therapy of metastatic breast cancer. ( Manni, A, 1987) |
| "The study purpose was to evaluate aminoglutethimide (AG) as adjuvant therapy in patients with primary node-positive breast cancer in a randomized double-blind placebo-controlled trial." | 9.07 | Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. ( Coombes, RC; Easton, D; Ford, HT; Jones, AL; Law, M; McKinna, JA; Nash, A; Powles, TJ; Smith, IE; Tidy, A, 1992) |
| "Trilostane and Aminoglutethimide, each given with a physiological replacement dose of hydrocortisone, were randomly allocated to 72 eligible postmenopausal advanced breast cancer patients; following treatment failure on either drug the patient continued with the other drug, if in a suitable clinical condition." | 9.07 | Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. ( Barley, VL; Blackledge, GR; Rowland, CG; Tyrrell, CJ; Williams, CJ, 1993) |
| "The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer." | 9.06 | Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986) |
| "One hundred and one postmenopausal patients with advanced breast cancer were enrolled in a randomized phase II clinical trial to investigate the clinical and hormonal response to aminoglutethimide administered at daily doses of 2 x 125 mg, 3 x 125 mg or 2 x 250 mg, with no addition of hydrocortisone." | 9.06 | Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Bonfrer, JM; Bruning, PF; de Jong-Bakker, M; Hart, AA; Moolenaar, AJ; Nooijen, WJ; van der Linden, E, 1989) |
| "Three hundred and twenty-two postmenopausal patients with primary breast cancer and ipsilateral axillary node involvement were randomized to receive aminoglutethimide and hydrocortisone or placebo for 2 years in a double blind randomized trial between April 1980 and March 1985." | 9.06 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. ( Bradbeer, J; Chilvers, C; Coombes, RC; Easton, D; Ford, HT; McKinna, A; Powles, TJ; Smith, IE; White, H; Yarnold, J, 1987) |
| "A group of 122 postmenopausal patients with histologically proven node-positive primary breast cancer have been randomized to receive aminoglutethimide-hydrocortisone or placebo aminoglutethimide-placebo hydrocortisone for 2 years." | 9.05 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. ( Bettelheim, R; Chilvers, C; Coombes, RC; Dowsett, M; Ford, HT; Gazet, JC; Gordon, C; Powles, TJ; Smith, IE; Zava, D, 1982) |
| "Sixty-six post-menopausal women with metastatic breast cancer were randomised to receive tamoxifen or tamoxifen with aminoglutethimide." | 9.05 | A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer. ( Calman, K; Campbell-Ferguson, J; Habeshaw, T; Kaye, S; Macbeth, F; Milsted, R; Sangster, G; Smith, D, 1985) |
| "222 patients with disseminated breast cancer have been randomised to receive either a combination of hormone therapies using tamoxifen, aminoglutethimide with hydrocortisone, and danazol (TAD), or tamoxifen alone." | 9.05 | Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. ( Ashley, S; Coombes, RC; Ford, HT; Gazet, JC; Nash, AG; Neville, AM; Powles, TJ, 1984) |
| "The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid." | 9.05 | Aminoglutethimide dose and hormone suppression in advanced breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983) |
| "The endocrine effects of replacement doses of hydrocortisone in postmenopausal women with advanced breast cancer were compared with the same doses of hydrocortisone plus aminoglutethimide." | 9.05 | Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1984) |
| "Plasma insulin-like growth factor-I (IGF-I) was measured in breast cancer patients before and during treatment with tamoxifen, goserelin or aminoglutethimide." | 7.68 | Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. ( Aakvaag, A; Johannessen, DC; Lien, EA; Lønning, PE, 1992) |
| "Aminoglutethimide is effective in the treatment of breast cancer in postmenopausal patients as a result of its inhibition of aromatase." | 7.68 | Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. ( Cantwell, BM; Dowsett, M; Harris, AL; Mehta, A, 1991) |
| "In an attempt to define the activity and toxicity of low-dose aminoglutethimide plus steroid replacement in advanced breast cancer, we treated 40 patients with aminoglutethimide 500 mg/day + hydrocortisone 50 mg/day." | 7.67 | Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies. ( Ambroso, G; Crivellari, D; Frustaci, S; Galligioni, E; Gasparini, G; Lo Re, G; Monfardini, S; Talamini, R; Vaccher, E, 1989) |
| "Eighty-seven consecutive patients with metastatic breast cancer were treated with aminoglutethimide plus hydrocortisone." | 7.67 | Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments. ( Bonadonna, G; Brambilla, C; Tancini, G; Zambetti, M, 1987) |
| "Seventy-two women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone (AG)." | 7.67 | Aminoglutethimide as second line therapy in advanced breast cancer. ( Blomqvist, C; Elomaa, I; Rissanen, P, 1986) |
| "Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%." | 7.67 | [The use of aminoglutethimide (orimeten) in disseminated breast cancer]. ( Bassalyk, LS; Garin, AM; Lichinitser, MR; Nadezhdina, TM; Vyshinskaia, GV, 1987) |
| "In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%)." | 7.67 | Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status. ( Bezwoda, WR; Browde, S; Dansey, RD; Hesdorffer, CS, 1987) |
| "Aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily was used to treat 76 postmenopausal women with advanced breast cancer." | 7.67 | Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Cantwell, BM; Dawes, PJ; Evans, RG; Farndon, J; Harris, AL; Needham, G; Sainsbury, JR; Wilson, R, 1986) |
| "In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation." | 7.67 | Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986) |
| "Eighteen premenopausal patients with progressive metastatic breast cancer were treated with aminoglutethimide (AG)/cortisone." | 7.67 | Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1986) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 7.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "5 mg, twice a day) aminoglutethimide (AG), without hydrocortisone (HC), escalating at monthly intervals to a conventional dose of AG (500 mg twice a day) combined with HC, were studied in 33 postmenopausal breast cancer patients." | 7.67 | Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. ( D'Souza, A; Donaldson, A; Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE; Stuart-Harris, R, 1985) |
| "Serum aminoglutethimide (AG) and N-acetylaminoglutethimide (NAG) concentrations were measured by high pressure liquid chromatography (HPLC) in 24 postmenopausal women with advanced breast cancer receiving increasing doses of oral AG." | 7.67 | Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer. ( Bradbrook, I; Morrison, P; Rogers, HJ; Smith, IE; Stuart-Harris, R, 1985) |
| "Fifty-seven patients with actively progressing advanced breast cancer have been assessed for their response to low-dose aminoglutethimide (125 mg bd) without steroid replacement." | 7.67 | Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. ( Murray, R; Pitt, P, 1985) |
| "Thirty-one postmenopausal patients with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1 000 - 1 250 mg/d) plus hydrocortisone replacement." | 7.67 | Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment. ( Bezwoda, WR; Browde, S; Derman, DP; Goss, G; Lange, M, 1984) |
| "In a phase II clinical trial, 38 postmenopausal women with advanced breast cancer were treated with aminoglutethimide and replacement hydrocortisone." | 7.67 | Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer. ( Bonfrèr, JG; Bruning, PF; de Jong-Bakker, M; Engelsman, E; Hamersma-vd Linden, E; Nooyen, W, 1984) |
| "One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)." | 7.67 | Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986) |
| "From July 1980 to June 1983, 61 postmenopausal women with progressive metastatic breast cancer were treated with aminoglutethimide, 250 mg 4 times daily, plus cortisone acetate, 25 mg twice daily." | 7.67 | Aminoglutethimide in advanced breast cancer. ( Bella, M; Bisagni, G; Ceci, G; Cocconi, G; Passalacqua, R, 1985) |
| "Thirty-four postmenopausal patients with advanced breast cancer had an overall objective response rate of 47% when treated with aminoglutethimide and hydrocortisone initially and a response rate of 24% when crossed over to therapy with tamoxifen after progression on aminoglutethimide." | 7.66 | Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. ( Boucher, AE; Dixon, RJ; Harvey, HA; Lipton, A; Santen, RJ; Shafik, AS; White, DS, 1982) |
| "Aminoglutethimide in combination with hydrocortisone provides an effective therapy in postmenopausal advanced breast cancer patients, with response rates of 37." | 7.66 | Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; McKinna, JA; Morgan, M; Smith, IE, 1982) |
| "Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy." | 7.66 | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1983) |
| "Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women." | 7.66 | Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. ( Cox, CE; Harvey, HA; Lawrence, BV; Lipton, A; Santen, RJ; Smart, EK; Wells, SA; White, DS, 1980) |
| "Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone." | 7.66 | Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Powles, TJ; Smith, IE; White, H, 1983) |
| "Aminoglutethimide in combination with dexamethasone has been used in 44 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptors." | 7.66 | Aminoglutethimide in the treatment of metastatic breast cancer. ( Troner, MB, 1982) |
| "A group of 213 unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide, 250 mg 4 times a day, and hydrocortisone, 20 mg 2 times a day." | 7.66 | Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. ( Harris, AL; Powles, TJ; Smith, IE, 1982) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 6.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer." | 6.16 | Tamoxifen therapy of metastatic breast cancer. ( Manni, A, 1987) |
| " This dosage regimen appears of comparable efficacy to previously reported higher dosage regimens with reduced toxicity compared to low dose regimens without hydrocortisone." | 5.28 | Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. ( Cantwell, BM; Carmichael, J; Dawes, P; Farndon, J; Harris, AL; Robinson, A; Wilson, R, 1989) |
| "As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer." | 5.28 | [The use of aminoglutethimide in the treatment of metastatic breast cancer]. ( Bellora, MG; Bergamino, T; Ciancio, A; Ferrero, A; Sismondi, P; Zola, P, 1991) |
| "Its role in the biology of breast cancer is unclear." | 5.26 | Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ( Bird, CE; Clark, AF; Masters, V; Sterns, EE, 1982) |
| "In order to evaluate the effectiveness of second and third line hormone therapy for postmenopausal (spontaneous or surgical) women with metastatic tamoxifen-resistant breast cancer, 293 women aged 36 to 91 (mean 63." | 5.07 | [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]. ( Ayme, Y; Carton, M; Daban, A; Delozier, T; Fargeot, P; Ferri, L; Fumoleau, P; Garcia-Giralt, E; Gorins, A; Omodei Zorini, C, 1994) |
| "Trilostane and Aminoglutethimide, each given with a physiological replacement dose of hydrocortisone, were randomly allocated to 72 eligible postmenopausal advanced breast cancer patients; following treatment failure on either drug the patient continued with the other drug, if in a suitable clinical condition." | 5.07 | Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer. ( Barley, VL; Blackledge, GR; Rowland, CG; Tyrrell, CJ; Williams, CJ, 1993) |
| "The study purpose was to evaluate aminoglutethimide (AG) as adjuvant therapy in patients with primary node-positive breast cancer in a randomized double-blind placebo-controlled trial." | 5.07 | Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. ( Coombes, RC; Easton, D; Ford, HT; Jones, AL; Law, M; McKinna, JA; Nash, A; Powles, TJ; Smith, IE; Tidy, A, 1992) |
| "The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer." | 5.06 | Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986) |
| "Three hundred and twenty-two postmenopausal patients with primary breast cancer and ipsilateral axillary node involvement were randomized to receive aminoglutethimide and hydrocortisone or placebo for 2 years in a double blind randomized trial between April 1980 and March 1985." | 5.06 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. ( Bradbeer, J; Chilvers, C; Coombes, RC; Easton, D; Ford, HT; McKinna, A; Powles, TJ; Smith, IE; White, H; Yarnold, J, 1987) |
| "One hundred and one postmenopausal patients with advanced breast cancer were enrolled in a randomized phase II clinical trial to investigate the clinical and hormonal response to aminoglutethimide administered at daily doses of 2 x 125 mg, 3 x 125 mg or 2 x 250 mg, with no addition of hydrocortisone." | 5.06 | Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Bonfrer, JM; Bruning, PF; de Jong-Bakker, M; Hart, AA; Moolenaar, AJ; Nooijen, WJ; van der Linden, E, 1989) |
| "222 patients with disseminated breast cancer have been randomised to receive either a combination of hormone therapies using tamoxifen, aminoglutethimide with hydrocortisone, and danazol (TAD), or tamoxifen alone." | 5.05 | Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially. ( Ashley, S; Coombes, RC; Ford, HT; Gazet, JC; Nash, AG; Neville, AM; Powles, TJ, 1984) |
| "A group of 122 postmenopausal patients with histologically proven node-positive primary breast cancer have been randomized to receive aminoglutethimide-hydrocortisone or placebo aminoglutethimide-placebo hydrocortisone for 2 years." | 5.05 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. ( Bettelheim, R; Chilvers, C; Coombes, RC; Dowsett, M; Ford, HT; Gazet, JC; Gordon, C; Powles, TJ; Smith, IE; Zava, D, 1982) |
| "The effect of the dose of aminoglutethimide on the suppression of oestrone, oestradiol and dehydroepiandrosterone sulphate (DHAS) levels was studied in 36 women with advanced postmenopausal breast cancer, all of whom received 20 mg hydrocortisone twice daily as replacement glucocorticoid." | 5.05 | Aminoglutethimide dose and hormone suppression in advanced breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1983) |
| "The endocrine effects of replacement doses of hydrocortisone in postmenopausal women with advanced breast cancer were compared with the same doses of hydrocortisone plus aminoglutethimide." | 5.05 | Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1984) |
| "Altogether 117 patients with advanced breast cancer were treated with either tamoxifen 10 mg by mouth twice daily or aminoglutethimide 250 mg by mouth four times daily with hydrocortisone 20 mg twice daily in a randomised cross-over trial in which patients who failed to respond to the first treatment or relapsed while receiving it were switched to the other." | 5.05 | Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. ( Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Smith, IE; Villardo, A; Walsh, G; White, H, 1981) |
| "In a control randomized cross-over trial, 117 patients with advanced breast cancer were treated initially either with tamoxifen (10 mg p." | 5.05 | Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. ( Gazet, JC; Harris, AL; McKinna, JA; Morgan, M; Smith, IE, 1982) |
| "Aminoglutethimide (AG) has antitumor activity in disseminated breast cancer similar to that of surgical adrenalectomy." | 5.05 | The role of aromatase inhibitors in breast cancer. ( Powles, TJ, 1983) |
| "Sixty-six post-menopausal women with metastatic breast cancer were randomised to receive tamoxifen or tamoxifen with aminoglutethimide." | 5.05 | A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer. ( Calman, K; Campbell-Ferguson, J; Habeshaw, T; Kaye, S; Macbeth, F; Milsted, R; Sangster, G; Smith, D, 1985) |
| "We evaluated the comparative effects of aminoglutethimide (AG) on androgen and estrogen levels estrone ([E1], estradiol [E2], plasma dehydroepiandrosterone-sulfate [DHEA-S], testosterone [T], dihydrotestosterone [DHT], delta 4-androstenedione [delta 4-A]), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin in postmenopausal patients with breast cancer randomly allocated to either AG treatment or bilateral surgical adrenalectomy as a control group." | 4.76 | Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. ( Samojlik, E; Santen, RJ; Veldhuis, JD; Wells, SA, 1980) |
| "A major obstacle to the understanding of the mechanisms of action of aromatase inhibitors in breast cancer is the observation that plasma estrogens are sustained at about 30-50% of their control levels despite 85-95% inhibition of the conversion of tracer androstenedione (A) to estrone (E1)." | 3.69 | A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. ( Ekse, D; Lønning, PE, 1995) |
| "Aminoglutethimide is effective in the treatment of breast cancer in postmenopausal patients as a result of its inhibition of aromatase." | 3.68 | Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion. ( Cantwell, BM; Dowsett, M; Harris, AL; Mehta, A, 1991) |
| "Plasma insulin-like growth factor-I (IGF-I) was measured in breast cancer patients before and during treatment with tamoxifen, goserelin or aminoglutethimide." | 3.68 | Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. ( Aakvaag, A; Johannessen, DC; Lien, EA; Lønning, PE, 1992) |
| "Eleven postmenopausal patients with advanced breast cancer were assessed for their response and endocrine changes to low-dose aminoglutethimide (250 mg twice a day) therapy without steroid administration." | 3.68 | Low-dose aminoglutethimide therapy without glucocorticoid administration. Clinical and hormonal findings. ( Kahán, Z; Tóth, I; Vecsernyés, M, 1992) |
| "From July 1980 to June 1983, 61 postmenopausal women with progressive metastatic breast cancer were treated with aminoglutethimide, 250 mg 4 times daily, plus cortisone acetate, 25 mg twice daily." | 3.67 | Aminoglutethimide in advanced breast cancer. ( Bella, M; Bisagni, G; Ceci, G; Cocconi, G; Passalacqua, R, 1985) |
| "Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%." | 3.67 | [The use of aminoglutethimide (orimeten) in disseminated breast cancer]. ( Bassalyk, LS; Garin, AM; Lichinitser, MR; Nadezhdina, TM; Vyshinskaia, GV, 1987) |
| "The endocrine effects of aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily were assessed in 45 postmenopausal women with advanced breast cancer." | 3.67 | Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen. ( Cantwell, BM; Dowsett, M; Farndon, J; Harris, AL; Needham, G; Sainsbury, JR; Wilson, R, 1986) |
| "In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%)." | 3.67 | Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status. ( Bezwoda, WR; Browde, S; Dansey, RD; Hesdorffer, CS, 1987) |
| "One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)." | 3.67 | Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986) |
| "Eighty-seven consecutive patients with metastatic breast cancer were treated with aminoglutethimide plus hydrocortisone." | 3.67 | Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments. ( Bonadonna, G; Brambilla, C; Tancini, G; Zambetti, M, 1987) |
| "Fifty-seven patients with actively progressing advanced breast cancer have been assessed for their response to low-dose aminoglutethimide (125 mg bd) without steroid replacement." | 3.67 | Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. ( Murray, R; Pitt, P, 1985) |
| "5 mg, twice a day) aminoglutethimide (AG), without hydrocortisone (HC), escalating at monthly intervals to a conventional dose of AG (500 mg twice a day) combined with HC, were studied in 33 postmenopausal breast cancer patients." | 3.67 | Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. ( D'Souza, A; Donaldson, A; Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE; Stuart-Harris, R, 1985) |
| "Aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily was used to treat 76 postmenopausal women with advanced breast cancer." | 3.67 | Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer. ( Cantwell, BM; Dawes, PJ; Evans, RG; Farndon, J; Harris, AL; Needham, G; Sainsbury, JR; Wilson, R, 1986) |
| "In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation." | 3.67 | Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986) |
| "Seventy-two women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone (AG)." | 3.67 | Aminoglutethimide as second line therapy in advanced breast cancer. ( Blomqvist, C; Elomaa, I; Rissanen, P, 1986) |
| "Postmenopausal patients with metastatic breast cancer were treated with aminoglutethimide (AG) and high-dose medroxyprogesterone acetate (MPA)." | 3.67 | Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. ( Blijham, GH; Mellink, WA; Meulenberg, PM; Van Deijk, WA, 1985) |
| "Eighteen premenopausal patients with progressive metastatic breast cancer were treated with aminoglutethimide (AG)/cortisone." | 3.67 | Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1986) |
| "Thirty-one postmenopausal patients with advanced breast cancer either unresponsive to tamoxifen or progressing after responding to tamoxifen were treated with aminoglutethimide (1 000 - 1 250 mg/d) plus hydrocortisone replacement." | 3.67 | Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment. ( Bezwoda, WR; Browde, S; Derman, DP; Goss, G; Lange, M, 1984) |
| "In a phase II clinical trial, 38 postmenopausal women with advanced breast cancer were treated with aminoglutethimide and replacement hydrocortisone." | 3.67 | Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer. ( Bonfrèr, JG; Bruning, PF; de Jong-Bakker, M; Engelsman, E; Hamersma-vd Linden, E; Nooyen, W, 1984) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 3.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "Serum aminoglutethimide (AG) and N-acetylaminoglutethimide (NAG) concentrations were measured by high pressure liquid chromatography (HPLC) in 24 postmenopausal women with advanced breast cancer receiving increasing doses of oral AG." | 3.67 | Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer. ( Bradbrook, I; Morrison, P; Rogers, HJ; Smith, IE; Stuart-Harris, R, 1985) |
| "In an attempt to define the activity and toxicity of low-dose aminoglutethimide plus steroid replacement in advanced breast cancer, we treated 40 patients with aminoglutethimide 500 mg/day + hydrocortisone 50 mg/day." | 3.67 | Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies. ( Ambroso, G; Crivellari, D; Frustaci, S; Galligioni, E; Gasparini, G; Lo Re, G; Monfardini, S; Talamini, R; Vaccher, E, 1989) |
| "Serum prolactin concentrations were measured in 135 postmenopausal patients with advanced breast cancer prior to their treatment with one of 3 endocrine therapies: aminoglutethimide (AG), tamoxifen (T) + AG, or T + AG + danazol." | 3.66 | Prognostic significance of serum prolactin levels in advanced breast cancer. ( Coombes, RC; Dowsett, M; Harris, AL; Jeffcoate, SL; McGarrick, GE; Smith, IE, 1983) |
| "Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women." | 3.66 | Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. ( Cox, CE; Harvey, HA; Lawrence, BV; Lipton, A; Santen, RJ; Smart, EK; Wells, SA; White, DS, 1980) |
| "Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy." | 3.66 | Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, S; Smith, IE, 1983) |
| "Fifty-three women with actively progressing advanced breast cancer, who had all previously received tamoxifen, were treated with aminoglutethimide to induce medical adrenalectomy." | 3.66 | Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment. ( Murray, RM; Pitt, P, 1981) |
| "A group of 213 unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide, 250 mg 4 times a day, and hydrocortisone, 20 mg 2 times a day." | 3.66 | Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. ( Harris, AL; Powles, TJ; Smith, IE, 1982) |
| "Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone." | 3.66 | Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Powles, TJ; Smith, IE; White, H, 1983) |
| "Aminoglutethimide in combination with hydrocortisone provides an effective therapy in postmenopausal advanced breast cancer patients, with response rates of 37." | 3.66 | Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. ( Dowsett, M; Harris, AL; Jeffcoate, SL; McKinna, JA; Morgan, M; Smith, IE, 1982) |
| "Thirty-four postmenopausal patients with advanced breast cancer had an overall objective response rate of 47% when treated with aminoglutethimide and hydrocortisone initially and a response rate of 24% when crossed over to therapy with tamoxifen after progression on aminoglutethimide." | 3.66 | Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. ( Boucher, AE; Dixon, RJ; Harvey, HA; Lipton, A; Santen, RJ; Shafik, AS; White, DS, 1982) |
| "Aminoglutethimide in combination with dexamethasone has been used in 44 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptors." | 3.66 | Aminoglutethimide in the treatment of metastatic breast cancer. ( Troner, MB, 1982) |
| " This report gives the results of a detailed pharmacokinetic and endocrine study of PyG in ten patients." | 2.67 | Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. ( Coombes, RC; Dowsett, M; Haynes, B; Jarman, M; Jones, A; Lonning, P; MacNeill, F; Mehta, A; Newton, C; Powles, TJ, 1991) |
| "Tamoxifen has become the most commonly used endocrine therapy of advanced breast cancer due to its few side effects and an overall response rate of 35%, which has been obtained in randomized trials of tamoxifen compared with either ablative, additive or inhibitive treatment approaches." | 2.66 | Endocrine therapy of advanced breast cancer. ( Mouridsen, HT; Rose, C, 1988) |
| "Research using cell-lines of human breast cancer also suggests that anti-progestins and agents capable of antagonizing steroid-induced growth factors will inhibit tumour growth." | 2.37 | Fundamental research leading to improved endocrine therapy for breast cancer. ( Miller, WR, 1987) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 2.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| " This dosage regimen appears of comparable efficacy to previously reported higher dosage regimens with reduced toxicity compared to low dose regimens without hydrocortisone." | 1.28 | Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. ( Cantwell, BM; Carmichael, J; Dawes, P; Farndon, J; Harris, AL; Robinson, A; Wilson, R, 1989) |
| "As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer." | 1.28 | [The use of aminoglutethimide in the treatment of metastatic breast cancer]. ( Bellora, MG; Bergamino, T; Ciancio, A; Ferrero, A; Sismondi, P; Zola, P, 1991) |
| "Hormonotherapy of metastatic breast cancer was begun in 1896." | 1.28 | [Current status of hormonotherapy of metastatic cancer of the breast]. ( Namer, M, 1989) |
| "Patients with advanced, evaluable breast cancer were biopsied before the start of endocrine treatment, and ER and cAR measurements were performed." | 1.27 | Relationship of cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human breast cancer. ( Døskeland, SO; Ekanger, R; Kvinnsland, S; Thorsen, T, 1983) |
| "In order to mimic postmenopausal breast cancer, we ovariectomized rats after N-methyl-N-nitrosourea administration." | 1.27 | Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response. ( Coombes, RC; Easton, D; Goss, PE; Singh, D; Wilkinson, JR; Williams, JC, 1986) |
| "Hormone-dependent breast carcinomas respond to deprivation of biologically active estrogens with objectively quantifiable tumor regression." | 1.26 | Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. ( Boucher, A; Harvey, H; Lipton, A; Samojlik, E; Santen, RJ; Wells, SA; Worgul, TJ, 1982) |
| "Its role in the biology of breast cancer is unclear." | 1.26 | Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer. ( Bird, CE; Clark, AF; Masters, V; Sterns, EE, 1982) |
| " These findings led to development of a practical regimen of escalating aminoglutethimide dosage in combination with hydrocortisone for treatment of patients with breast carcinoma." | 1.26 | In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. ( Rosen, HR; Samojlik, E; Santen, RJ; Santner, SJ; Tilsen-Mallett, N; Veldhuis, JD, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 98 (86.73) | 18.7374 |
| 1990's | 15 (13.27) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruning, PF | 3 |
| Bonfrer, JM | 2 |
| De Jong-Bakker, M | 3 |
| Nooyen, W | 2 |
| Powles, TJ | 12 |
| Ashley, S | 1 |
| Ford, HT | 7 |
| Gazet, JC | 7 |
| Nash, AG | 3 |
| Neville, AM | 2 |
| Coombes, RC | 11 |
| Harvey, HA | 4 |
| Lipton, A | 11 |
| White, DS | 2 |
| Santen, RJ | 21 |
| Boucher, AE | 3 |
| Shafik, AS | 1 |
| Dixon, RJ | 1 |
| Chilvers, C | 3 |
| Dowsett, M | 15 |
| Bettelheim, R | 1 |
| Gordon, C | 1 |
| Smith, IE | 20 |
| Zava, D | 1 |
| Harris, AL | 19 |
| Jeffcoate, SL | 7 |
| McKinna, JA | 5 |
| Morgan, M | 4 |
| Ingle, JN | 1 |
| Jeffcoate, S | 2 |
| Scaglia, HE | 1 |
| Koliren, L | 1 |
| Loruso, A | 1 |
| Zylbersztein, C | 1 |
| Ramos, G | 1 |
| Díaz, L | 1 |
| Soto, E | 1 |
| Stuart-Harris, RC | 1 |
| Wells, SA | 10 |
| Bird, CE | 1 |
| Masters, V | 1 |
| Sterns, EE | 1 |
| Clark, AF | 1 |
| Samojlik, E | 11 |
| Worgul, TJ | 3 |
| Kvinnsland, S | 3 |
| Ekanger, R | 1 |
| Døskeland, SO | 1 |
| Thorsen, T | 2 |
| Moiseenko, VM | 1 |
| Semiglazov, VF | 1 |
| Mason, RC | 1 |
| Chetty, U | 2 |
| Miller, WR | 2 |
| Hawkins, RA | 2 |
| Forrest, AP | 3 |
| Bezwoda, WR | 2 |
| Derman, DP | 1 |
| Browde, S | 2 |
| Goss, G | 1 |
| Lange, M | 1 |
| Bonfrèr, JG | 1 |
| Engelsman, E | 1 |
| Hamersma-vd Linden, E | 1 |
| Vermeulen, A | 1 |
| Paridaens, R | 1 |
| Heuson, JC | 1 |
| Harmer, CL | 2 |
| White, H | 3 |
| Parsons, CA | 2 |
| Mitchell, MD | 1 |
| Boucher, A | 3 |
| White, D | 3 |
| Bernath, A | 2 |
| Dixon, R | 2 |
| Richards, G | 2 |
| Shafik, A | 2 |
| Szepesi, T | 1 |
| Schratter-Sehn, AU | 1 |
| Villardo, A | 1 |
| Walsh, G | 1 |
| McGarrick, GE | 1 |
| Veldhuis, JD | 2 |
| Harvey, H | 6 |
| Smart, E | 1 |
| Cox, C | 1 |
| Kirschner, MA | 1 |
| Ertel, NH | 1 |
| Santner, SJ | 2 |
| Tilsen-Mallett, N | 1 |
| Rosen, HR | 1 |
| Troner, MB | 1 |
| Rees, LH | 1 |
| Ratcliffe, WA | 1 |
| Henk, M | 1 |
| Murray, RM | 1 |
| Pitt, P | 2 |
| Henderson, IC | 2 |
| Canellos, GP | 1 |
| Lawrence, BV | 1 |
| Cox, CE | 1 |
| Smart, EK | 1 |
| Garcia-Giralt, E | 2 |
| Omodei Zorini, C | 1 |
| Ferri, L | 1 |
| Ayme, Y | 2 |
| Carton, M | 2 |
| Daban, A | 2 |
| Delozier, T | 2 |
| Fargeot, P | 2 |
| Fumoleau, P | 2 |
| Gorins, A | 2 |
| Williams, CJ | 1 |
| Barley, VL | 1 |
| Blackledge, GR | 1 |
| Rowland, CG | 1 |
| Tyrrell, CJ | 1 |
| Guerin, D | 1 |
| Guerin, R | 1 |
| Lønning, PE | 5 |
| Ekse, D | 2 |
| Veldhuis, J | 2 |
| Ruby, EB | 1 |
| Kendall, J | 1 |
| Santner, S | 1 |
| Davis, B | 1 |
| Ruby, E | 1 |
| Haagensen, DE | 1 |
| Ruby, EJ | 1 |
| Dilley, WG | 1 |
| Jones, AL | 1 |
| Law, M | 1 |
| Tidy, A | 1 |
| Easton, D | 4 |
| Nash, A | 1 |
| Lien, EA | 1 |
| Johannessen, DC | 1 |
| Aakvaag, A | 2 |
| Kahán, Z | 1 |
| Tóth, I | 1 |
| Vecsernyés, M | 1 |
| Mehta, A | 2 |
| Cantwell, BM | 5 |
| Bellora, MG | 1 |
| Ciancio, A | 1 |
| Ferrero, A | 1 |
| Bergamino, T | 1 |
| Zola, P | 1 |
| Sismondi, P | 1 |
| Namer, M | 2 |
| Henry, JA | 1 |
| Piggott, NH | 1 |
| Mallick, UK | 1 |
| Nicholson, S | 1 |
| Farndon, JR | 1 |
| Westley, BR | 1 |
| May, FE | 1 |
| MacNeill, F | 1 |
| Newton, C | 1 |
| Haynes, B | 1 |
| Jones, A | 1 |
| Jarman, M | 1 |
| Lonning, P | 1 |
| Voznyĭ, EK | 1 |
| Meshcheriakova, NG | 1 |
| Biakhov, MIu | 1 |
| Vasiuta, NIu | 1 |
| Lundgren, S | 1 |
| Anderson, ED | 1 |
| Levack, PA | 1 |
| Hart, AA | 1 |
| van der Linden, E | 1 |
| Moolenaar, AJ | 1 |
| Nooijen, WJ | 1 |
| Carmichael, J | 1 |
| Dawes, P | 1 |
| Robinson, A | 1 |
| Farndon, J | 3 |
| Wilson, R | 3 |
| Crivellari, D | 1 |
| Galligioni, E | 1 |
| Frustaci, S | 1 |
| Gasparini, G | 1 |
| Vaccher, E | 1 |
| Lo Re, G | 1 |
| Talamini, R | 1 |
| Monfardini, S | 1 |
| Ambroso, G | 1 |
| Andersen, J | 1 |
| Poulsen, HS | 1 |
| Ceci, G | 1 |
| Passalacqua, R | 1 |
| Bisagni, G | 1 |
| Bella, M | 1 |
| Cocconi, G | 1 |
| Stuart-Harris, R | 3 |
| Hill, M | 1 |
| Sainsbury, JR | 2 |
| Needham, G | 2 |
| Wander, HE | 3 |
| Nagel, GA | 3 |
| Blossey, HC | 2 |
| Kleeberg, U | 1 |
| Manni, A | 1 |
| D'Souza, A | 1 |
| Donaldson, A | 1 |
| Elomaa, I | 1 |
| Blomqvist, C | 1 |
| Rissanen, P | 1 |
| Alonso-Muñoz, MC | 1 |
| Ojeda-González, MB | 1 |
| Beltran-Fabregat, M | 1 |
| Dorca-Ribugent, J | 1 |
| López-López, L | 1 |
| Borrás-Balada, J | 1 |
| Cardenal-Alemany, F | 1 |
| Gómez-Batiste, X | 1 |
| Fabregat-Mayol, J | 1 |
| Viladiu-Quemada, P | 1 |
| Rose, C | 3 |
| Mouridsen, HT | 2 |
| Huang, HY | 1 |
| Van Deijk, WA | 1 |
| Blijham, GH | 1 |
| Mellink, WA | 1 |
| Meulenberg, PM | 1 |
| Teichmann, AT | 1 |
| Cremer, P | 1 |
| Wieland, H | 1 |
| Kruse, B | 1 |
| Kuhn, W | 1 |
| Seidel, D | 1 |
| Grem, JL | 1 |
| Falkson, G | 1 |
| Love, RR | 1 |
| Tormey, DC | 1 |
| Thomas, L | 1 |
| Adcock, H | 1 |
| Bradbeer, J | 2 |
| Kamby, C | 2 |
| Bastholt, L | 1 |
| Brincker, H | 1 |
| Skovgaard-Poulsen, H | 1 |
| Andersen, AP | 1 |
| Loft, H | 1 |
| Dombernowsky, P | 1 |
| Andersen, KW | 1 |
| McKinna, A | 1 |
| Yarnold, J | 1 |
| Nadezhdina, TM | 1 |
| Vyshinskaia, GV | 1 |
| Lichinitser, MR | 1 |
| Bassalyk, LS | 1 |
| Garin, AM | 1 |
| Dansey, RD | 1 |
| Hesdorffer, CS | 1 |
| Gorgone, S | 1 |
| Lorenzini, C | 1 |
| Palmeri, R | 1 |
| Belnome, N | 1 |
| Calbo, L | 1 |
| Dattola, P | 1 |
| Melita, P | 1 |
| Zambetti, M | 1 |
| Brambilla, C | 1 |
| Tancini, G | 1 |
| Bonadonna, G | 1 |
| Brodie, AM | 1 |
| Wing, LY | 1 |
| Goss, P | 1 |
| Wilkinson, JR | 1 |
| Williams, JC | 1 |
| Singh, D | 1 |
| Goss, PE | 1 |
| Evans, RG | 1 |
| Dawes, PJ | 1 |
| Höffken, K | 3 |
| Kempf, H | 1 |
| Miller, AA | 3 |
| Miller, B | 3 |
| Schmidt, CG | 3 |
| Faber, P | 1 |
| Kley, HK | 1 |
| Becher, R | 2 |
| Aulbert, E | 1 |
| Hoffmann, B | 1 |
| Anders, CU | 1 |
| Callies, R | 1 |
| Berry, J | 1 |
| Green, BJ | 1 |
| Matheson, DS | 1 |
| Repetto, L | 1 |
| Pronzato, P | 1 |
| Ardizzoni, A | 1 |
| Bertelli, G | 1 |
| Gulisano, M | 1 |
| Amoroso, D | 1 |
| Gardin, G | 1 |
| Fusco, V | 1 |
| Falcone, A | 1 |
| Conte, PF | 1 |
| Paterson, AH | 1 |
| Milsted, R | 1 |
| Habeshaw, T | 1 |
| Kaye, S | 1 |
| Sangster, G | 1 |
| Macbeth, F | 1 |
| Campbell-Ferguson, J | 1 |
| Smith, D | 1 |
| Calman, K | 1 |
| Alberto, P | 1 |
| Mermillod, B | 1 |
| Kaplan, E | 1 |
| Goldhirsch, A | 1 |
| Obrecht, JP | 1 |
| Jungi, F | 1 |
| Martz, G | 1 |
| Barrelet, L | 1 |
| Cavalli, F | 1 |
| Bradbrook, I | 1 |
| Morrison, P | 1 |
| Rogers, HJ | 1 |
| Murray, R | 1 |
11 reviews available for aminoglutethimide and Menopause
| Article | Year |
|---|---|
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
[Hormone therapy of patients with breast cancer].
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Castration; Combined Modality Therapy; Drug Resi | 1984 |
Beatson: hormones and the management of breast cancer.
Topics: Adult; Aging; Aminoglutethimide; Breast; Breast Neoplasms; Estrogens; Female; Hormones; Humans; Meno | 1982 |
[Hormones and tumor therapy: current clinical status and future developments in endocrine therapy of breast cancer].
Topics: Adrenal Cortex Hormones; Adrenalectomy; Aminoglutethimide; Androgens; Breast Neoplasms; Castration; | 1982 |
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androgens; Breast Neoplasms; Castration; Estrogens; Female; | 1980 |
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy | 1977 |
Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
Topics: Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Fadrozole; Fe | 1990 |
Tamoxifen therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clin | 1987 |
Fundamental research leading to improved endocrine therapy for breast cancer.
Topics: Adrenal Cortex Hormones; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Combined Modali | 1987 |
Could aminoglutethimide replace adrenalectomy?
Topics: Adrenal Cortex; Adrenalectomy; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials | 1985 |
[Hormone therapy of metastatic breast carcinoma].
Topics: Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Buserelin; Female; | 1985 |
30 trials available for aminoglutethimide and Menopause
| Article | Year |
|---|---|
Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1984 |
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Dehydroepiandrosterone; | 1982 |
Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone Sul | 1983 |
Additive hormonal therapy in women with advanced breast cancer.
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Clinical Trials as Topic; Danazol; Drug Therapy, Com | 1984 |
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone | 1984 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
Ablative procedures in patients with metastatic breast carcinoma.
Topics: Adrenal Cortex; Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Clinica | 1984 |
The role of aromatase inhibitors in breast cancer.
Topics: Aged; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1983 |
A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Castration; Clinical Trials as Topic; Female; Humans; Menopause | 1982 |
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Res | 1981 |
Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combinatio | 1982 |
Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Hydroc | 1982 |
Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Castration; Clinical Trials as Topic; Drug Admi | 1982 |
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Resistance; Female; Humans | 1994 |
Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Adrenal Cortex Hormones; Aged; Aminoglutethimide; Antineoplastic Ag | 1993 |
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Resistance; Female; Humans | 1992 |
Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Huma | 1992 |
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
Topics: Aged; Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Biological Availability; Breas | 1991 |
Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Drug Evaluation; | 1989 |
Tamoxifen therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clin | 1987 |
Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cl | 1988 |
Endocrine therapy of advanced breast cancer.
Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Hor | 1988 |
A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Doub | 1986 |
Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 1986 |
Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Dose | 1987 |
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1987 |
Metastatic pattern and response to endocrine therapy in human breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Diethylstilbestrol; Female; Fluoxymesterone; Humans; Medroxypro | 1986 |
A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical | 1985 |
A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therap | 1985 |
Could aminoglutethimide replace adrenalectomy?
Topics: Adrenal Cortex; Adrenalectomy; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials | 1985 |
75 other studies available for aminoglutethimide and Menopause
| Article | Year |
|---|---|
Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
Topics: Adrenocorticotropic Hormone; Aminoglutethimide; Breast Neoplasms; Cosyntropin; Drug Therapy, Combina | 1984 |
Aminoglutethimide.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Neoplasms, Hormon | 1981 |
Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Menopause; Middle Aged; Neoplas | 1982 |
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Topics: Adult; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandro | 1982 |
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Cos | 1983 |
Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer.
Topics: Adult; Aged; Aldosterone; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dehydroepiandrosteron | 1984 |
The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aminoglutethimide; Antineoplastic Agents; Breast Neopla | 1980 |
Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer.
Topics: Adenocarcinoma; Adult; Aminoglutethimide; Androstenediol; Androstenediols; Breast Neoplasms; Carcino | 1982 |
Plasma estrone-sulfate: assessment of reduced estrogen production during treatment of metastatic breast carcinoma.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Estrogens, Conjugated (USP); Estron | 1982 |
Relationship of cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Cyclic AMP; Cytosol; Female; Humans; M | 1983 |
Aminoglutethimide and advanced breast cancer [proceedings].
Topics: Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Female; Humans; Kinetics; Menopause; Re | 1980 |
Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamid | 1984 |
Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Menopause; Middle Aged; Thyrotr | 1984 |
Aminoglutethimide as an aromatase inhibitor in the treatment of cancer.
Topics: Aminoglutethimide; Androgens; Animals; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Hu | 1984 |
Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
Topics: Aminoglutethimide; Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estr | 1984 |
Effects of aminoglutethimide on adrenal steroid secretion.
Topics: Adrenal Cortex Hormones; Aged; Aminoglutethimide; Androgens; Estrogens; Female; Humans; Hydrocortiso | 1983 |
Aminoglutethimide for the treatment of advanced postmenopausal breast cancer.
Topics: Adult; Age Factors; Aged; Aminoglutethimide; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combin | 1983 |
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Hormones; Humans; Me | 1983 |
Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer.
Topics: 6-Ketoprostaglandin F1 alpha; Aminoglutethimide; Breast Neoplasms; Dinoprost; Female; Humans; Menopa | 1983 |
Prognostic significance of serum prolactin levels in advanced breast cancer.
Topics: Aminoglutethimide; Breast Neoplasms; Danazol; Drug Therapy, Combination; Female; Humans; Menopause; | 1983 |
Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Glucocorticoids; Humans; Menopaus | 1982 |
Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Topics: Adrenal Glands; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Castration; Estradiol; Es | 1982 |
In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Topics: Adrenal Cortex; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Dexamethasone; Drug Admin | 1982 |
Aminoglutethimide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dexamethasone; Drug Therapy, Combi | 1982 |
Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.
Topics: Age Factors; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Evaluation; Drug Therapy, Com | 1982 |
Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
Topics: Aminoglutethimide; Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dana | 1982 |
Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Drug Resistance; Estrog | 1981 |
Cancer of the breast: the past decade (second of two parts).
Topics: Adrenalectomy; Adult; Age Factors; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Castr | 1980 |
Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy.
Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Neoplasms, Hormone-Depe | 1980 |
A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 1995 |
Mechanism of action of aminoglutethimide in breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Estradiol; Estrogen Antagonists; | 1979 |
Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Topics: 17-alpha-Hydroxypregnenolone; Aminoglutethimide; Androgens; Androstenedione; Breast Neoplasms; Castr | 1978 |
Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma.
Topics: Adult; Aminoglutethimide; Androstenedione; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; | 1978 |
Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.
Topics: Adrenal Cortex; Adrenalectomy; Aldosterone; Aminoglutethimide; Androstenedione; Bone Neoplasms; Brea | 1978 |
Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
Topics: Adrenal Glands; Aminoglutethimide; Androstenedione; Breast Neoplasms; Castration; Estradiol; Estroge | 1977 |
Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Buserelin; Cortisone; Female; Goserelin; | 1992 |
Low-dose aminoglutethimide therapy without glucocorticoid administration. Clinical and hormonal findings.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Glucocorticoids; Hormones; Humans; Menopause; Mid | 1992 |
Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
Topics: 17-alpha-Hydroxyprogesterone; Adrenocorticotropic Hormone; Aminoglutethimide; Androstenedione; Breas | 1991 |
[The use of aminoglutethimide in the treatment of metastatic breast cancer].
Topics: Adrenal Glands; Age Factors; Aminoglutethimide; Androstenedione; Breast Neoplasms; Female; Humans; M | 1991 |
[Reflexions on hormone therapy of cancer of the breast].
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Humans; Medroxyprogesterone Aceta | 1991 |
pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.
Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Immuno | 1991 |
[Hormonal control of disseminated breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Delayed-Action Preparations; Estrogen An | 1990 |
Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.
Topics: Administration, Oral; Aged; Aminoglutethimide; Breast Neoplasms; Drug Interactions; Female; Humans; | 1990 |
Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Buserelin; Female; Goserelin; Humans; Menopaus | 1989 |
[Current status of hormonotherapy of metastatic cancer of the breast].
Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Humans; Hydrocortisone; Medroxypr | 1989 |
Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1989 |
Low-dose aminoglutethimide plus steroid replacement in advanced breast cancer patients resistant to conventional therapies.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; B | 1989 |
Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diethylst | 1989 |
Aminoglutethimide in advanced breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Aminoglutethimide; Breast Neoplasms; Female; gamma-Glutamyltransf | 1985 |
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Dehydroep | 1985 |
Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1986 |
Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brea | 1986 |
Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Topics: Adrenocorticotropic Hormone; Aged; Aminoglutethimide; Androstenedione; Aromatase Inhibitors; Breast | 1985 |
Aminoglutethimide as second line therapy in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brea | 1986 |
[Experience in treating 20 cases of postmenopausal advanced breast cancer].
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Thoracic N | 1986 |
Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Medr | 1985 |
[Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
Topics: Aminoglutethimide; Breast Neoplasms; Cholesterol; Cortisone; Drug Therapy, Combination; Female; Huma | 1985 |
A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1988 |
[The use of aminoglutethimide (orimeten) in disseminated breast cancer].
Topics: Adult; Aminoglutethimide; Breast Neoplasms; Female; Follow-Up Studies; Humans; Menopause; Middle Age | 1987 |
Use of aminoglutethimide for the treatment of advanced breast cancer. Clinical correlations with previous treatment, oestrogen-receptor and menstrual status.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Evaluation Stud | 1987 |
[Aminoglutethimide in the treatment of metastasizing breast carcinoma in old age].
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged | 1987 |
Aminoglutethimide in postmenopausal breast cancer refractory to multiple hormonal and cytostatic treatments.
Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Men | 1987 |
Aromatase inhibitors and the treatment of breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Animals; Aromatase Inhibitors; Breast Neoplasms; Es | 1986 |
Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response.
Topics: Aminoglutethimide; Androstenedione; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast | 1986 |
Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Resp | 1986 |
Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.
Topics: Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; Estradiol; Estrogens; Estrone; Fe | 1986 |
Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Evaluation; Female; Hormones; | 1986 |
[Low-dose aminoglutethimide therapy without cortisol substitution in postmenopause metastasizing breast cancer].
Topics: Aminoglutethimide; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; Huma | 1986 |
Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Cell Line; Cytotoxicity, Immunologic; Estradiol; Female; | 1987 |
Metastatic breast cancer: an analysis of prognostic factors in patients treated with aminoglutethimide.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged; Ovariectom | 1987 |
Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer.
Topics: Adult; Aminoglutethimide; Breast Neoplasms; Cortisone; Female; Humans; Menopause; Middle Aged; Neopl | 1986 |
Chemotherapy and hormone therapy of metastatic breast cancer.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali | 1985 |
Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Administration | 1985 |
Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Cortisone; Female; Fludrocortisone; Humans; Menopa | 1985 |
Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer.
Topics: Adrenal Glands; Adrenalectomy; Adult; Aged; Aminoglutethimide; Binding, Competitive; Breast Neoplasm | 1974 |